{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:32:18Z","timestamp":1792276338661,"version":"4.4.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"vor","delay-in-days":1462,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.kint.2016.02.026","type":"journal-article","created":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T09:51:39Z","timestamp":1464861099000},"page":"41-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":222,"title":["Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences"],"prefix":"10.1016","volume":"90","author":[{"given":"Nosratola D.","family":"Vaziri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2016.02.026_bib1","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1046\/j.1523-1755.2003.00941.x","article-title":"Molecular mechanisms of lipid dysregulation in nephrotic syndrome","volume":"63","author":"Vaziri","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.02.026_bib2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1056\/NEJM199008303230905","article-title":"Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome","volume":"323","author":"Joven","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.02.026_bib3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/j.1523-1755.1998.00831.x","article-title":"Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis","volume":"53","author":"de Sain-van der Velden","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.02.026_bib4","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1172\/JCI111548","article-title":"Catabolism of very low density\u00a0lipoproteins in experimental nephrosis","volume":"74","author":"Garber","year":"1984","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2016.02.026_bib5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ki.1991.190","article-title":"Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic range proteinuria","volume":"40","author":"Warwick","year":"1991","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.02.026_bib6","first-page":"F335","article-title":"Both peripheral chylomicron catabolism and hepatic uptake of remnants are defective in nephrosis","volume":"263","author":"Kaysen","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.kint.2016.02.026_bib7","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1172\/JCI114750","article-title":"Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat","volume":"86","author":"Davies","year":"1990","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2016.02.026_bib8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1523-1755.2001.00478.x","article-title":"Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome","volume":"59","author":"Shearer","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.02.026_bib9","doi-asserted-by":"crossref","first-page":"9252","DOI":"10.1073\/pnas.89.19.9252","article-title":"Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity","volume":"89","author":"Takahashi","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2016.02.026_bib10","doi-asserted-by":"crossref","first-page":"26411","DOI":"10.1016\/S0021-9258(18)47209-2","article-title":"Regulation of the very low density lipoprotein receptor by thyroid hormone in rat skeletal muscle","volume":"269","author":"Jokinen","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2016.02.026_bib11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/hmg\/3.4.531","article-title":"Characterization and tissue-specific expression of the human 'very low density lipoprotein (VLDL) receptor' mRNA","volume":"3","author":"Webb","year":"1994","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.kint.2016.02.026_bib12","doi-asserted-by":"crossref","first-page":"22391","DOI":"10.1016\/S0021-9258(17)31802-1","article-title":"Oligosaccharide sequences of endothelial cell surface heparan sulfate proteoglycan with affinity for lipoprotein lipase","volume":"269","author":"Parthasarathy","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2016.02.026_bib13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cmet.2007.02.002","article-title":"Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons","volume":"5","author":"Beigneux","year":"2007","journal-title":"Cell Metab"},{"key":"10.1016\/j.kint.2016.02.026_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/MOL.0b013e3281527914","article-title":"GPIHBP1\u2014an endothelial cell molecule required for the lipolytic processing of chylomicrons","volume":"18","author":"Young","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.kint.2016.02.026_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0005-2760(90)90025-S","article-title":"Experimental nephrotic syndrome: removal and tissue distribution of chylomicrons and very-low-density lipoproteins of normal and nephrotic origin","volume":"1043","author":"Levy","year":"1990","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.kint.2016.02.026_bib16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1523-1755.2002.00104.x","article-title":"Downregulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis","volume":"61","author":"Sato","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.02.026_bib17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0022-2143(97)90038-X","article-title":"Gene expression of lipoprotein lipase in experimental nephrosis","volume":"130","author":"Liang","year":"1997","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.kint.2016.02.026_bib18","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s10157-011-0549-3","article-title":"Lipoprotein lipase deficiency in chronic kidney disease is compounded by downregulation of endothelial GPIHBP1 expression","volume":"16","author":"Vaziri","year":"2012","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kint.2016.02.026_bib19","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1046\/j.1523-1755.2000.00278.x","article-title":"Patients with nephrotic-range proteinuria have apolipoprotein C and E deficient VLDL1","volume":"58","author":"Deighan","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.02.026_bib20","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/ki.2012.244","article-title":"Proteinuria decreases tissue lipoprotein receptor levels resulting in altered lipoprotein structure and increasing lipid levels","volume":"82","author":"Wang","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.02.026_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrneph.2015.180","article-title":"HDL abnormalities in nephrotic syndrome and chronic kidney disease","volume":"12","author":"Vaziri","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2016.02.026_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1523-1755.2004.00373.x","article-title":"Nephrotic livers secrete normal VLDL that acquire structural and functional defects following interaction with HDL","volume":"65","author":"Shearer","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.02.026_bib23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/0026-0495(87)90050-3","article-title":"Glycosaminoglycans and chylomicron metabolism in control and nephrotic rats","volume":"36","author":"Staprans","year":"1987","journal-title":"Metabolism"},{"key":"10.1016\/j.kint.2016.02.026_bib24","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/ki.1997.263","article-title":"Down-regulation of hepatic lipase expression in experimental nephrotic syndrome","volume":"51","author":"Liang","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.02.026_bib25","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1046\/j.1523-1755.2003.00281.x","article-title":"Protein restriction and AST-120 improve lipoprotein lipase, hepatic lipase and VLDL receptor in focal glomerulosclerosis","volume":"64","author":"Sato","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.02.026_bib26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1042\/BSR20110102","article-title":"Angiopoietin-like 4: a decade of research","volume":"32","author":"Zhu","year":"2012","journal-title":"Biosci Rep"},{"key":"10.1016\/j.kint.2016.02.026_bib27","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.bbrc.2009.12.145","article-title":"The acute phase response stimulates the expression of angiopoietin like protein 4","volume":"391","author":"Lu","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.kint.2016.02.026_bib28","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1194\/jlr.M900145-JLR200","article-title":"GPIHBP1 stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4","volume":"50","author":"Sonnenburg","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.kint.2016.02.026_bib29","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1194\/jlr.P015867","article-title":"Serum angiopoietin-like 4 protein levels and expression in adipose tissue are inversely correlated with obesity in monozygotic twins","volume":"52","author":"Robciuc","year":"2011","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.kint.2016.02.026_bib30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nm.2261","article-title":"Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome","volume":"17","author":"Clement","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2016.02.026_bib31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1053\/j.ajkd.2011.07.024","article-title":"New insights into human minimal change disease: lessons from animal models","volume":"59","author":"Chugh","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2016.02.026_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3396","article-title":"Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome","volume":"20","author":"Clement","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2016.02.026_bib33","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1152\/ajprenal.00099.2005","article-title":"Dyslipidemia of chronic renal failure: the nature, mechanisms and potential consequences","volume":"290","author":"Vaziri","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2016.02.026_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1542-4758.2006.01168.x","article-title":"Mechanisms of dyslipidemia of chronic renal failure","volume":"10","author":"Vaziri","year":"2006","journal-title":"Hemodialysis Int"},{"key":"10.1016\/j.kint.2016.02.026_bib35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/s-0030-1267917","article-title":"Serum levels of the adipokine fasting-induced adipose factor\/angiopoietin-like protein 4 depend on renal function","volume":"43","author":"Baranowski","year":"2011","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.kint.2016.02.026_bib36","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.ajkd.2014.04.016","article-title":"Dual role of circulating angiopoietin-like 4 (ANGPTL4) in promoting hypertriglyceridemia and lowering proteinuria in nephrotic syndrome","volume":"64","author":"Vaziri","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2016.02.026_bib37","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1038\/ki.1997.242","article-title":"Acquired VLDL receptor deficiency in experimental nephrosis","volume":"51","author":"Liang","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.02.026_bib38","doi-asserted-by":"crossref","first-page":"22887","DOI":"10.3390\/ijms151222887","article-title":"LRP-1: functions, signaling and implications in kidney and other diseases","volume":"15","author":"Lin","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2016.02.026_bib39","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1111\/j.1538-7836.2005.01371.x","article-title":"Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability","volume":"3","author":"Lillis","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.kint.2016.02.026_bib40","doi-asserted-by":"crossref","first-page":"152163","DOI":"10.1155\/2013\/152163","article-title":"LRP-1: a checkpoint for the extracellular matrix proteolysis","volume":"2013","author":"Etique","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.kint.2016.02.026_bib41","doi-asserted-by":"crossref","first-page":"E813","DOI":"10.1152\/ajpendo.00266.2004","article-title":"Upregulation of hepatic LDL receptor-related protein (LRP) in nephrotic syndrome: response to statin therapy","volume":"288","author":"Kim","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.kint.2016.02.026_bib42","doi-asserted-by":"crossref","first-page":"F662","DOI":"10.1152\/ajprenal.00046.2008","article-title":"Expression profiling of hepatic genes associated with lipid metabolism in nephrotic rats","volume":"295","author":"Zhou","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2016.02.026_bib43","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1523-1755.2004.00724.x","article-title":"Upregulation of hepatic acyl CoA diglycerol acyltransferase (DGAT)-1 expression in nephrotic syndrome","volume":"66","author":"Vaziri","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.02.026_bib44","first-page":"F755","article-title":"Apolipoprotein gene expression in analbuminemic rats and in rats with Heymann nephritis","volume":"262","author":"Sun","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/j.kint.2016.02.026_bib45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0026-0495(90)90074-M","article-title":"Low-density lipoprotein metabolism in the nephrotic syndrome","volume":"39","author":"Warwick","year":"1990","journal-title":"Metabolism"},{"key":"10.1016\/j.kint.2016.02.026_bib46","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/ki.1995.500","article-title":"Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis","volume":"48","author":"Vaziri","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.02.026_bib47","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1046\/j.1523-1755.2003.00911.x","article-title":"Molecular mechanism of altered cholesterol metabolism in focal glomerulosclerosis","volume":"63","author":"Vaziri","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.02.026_bib48","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.metabol.2007.05.007","article-title":"Hepatic tissue sterol regulatory element-binding protein-2 (SREBP-2) and LDL receptor in nephrotic syndrome","volume":"56","author":"Kim","year":"2007","journal-title":"Metabolism"},{"key":"10.1016\/j.kint.2016.02.026_bib49","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/ki.1996.118","article-title":"Gene expression of hepatic cholesterol 7 alpha-hydroxylase in the course of puromycin-induced nephrosis","volume":"49","author":"Liang","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.02.026_bib50","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1046\/j.1523-1755.2002.00319.x","article-title":"Upregulation of acyl-coenzyme a: cholesterol acyltransferase (ACAT) in nephrotic syndrome","volume":"61","author":"Vaziri","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.02.026_bib51","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/01.CIR.0000136023.70841.0F","article-title":"Acyl-CoA cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, LCAT, SRB-1 and LDL receptor deficiencies in nephrotic syndrome","volume":"110","author":"Vaziri","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2016.02.026_bib52","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/ki.1996.388","article-title":"Downregulation of hepatic LDL receptor expression in experimental nephrosis","volume":"50","author":"Vaziri","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.02.026_bib53","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1126\/science.1168974","article-title":"LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor","volume":"325","author":"Zelcer","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.kint.2016.02.026_bib54","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2016.02.026_bib55","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2016.02.026_bib56","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1042\/BJ20070664","article-title":"Harris. Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity","volume":"406","author":"Li","year":"2007","journal-title":"Biochem J"},{"key":"10.1016\/j.kint.2016.02.026_bib57","doi-asserted-by":"crossref","first-page":"20799","DOI":"10.1074\/jbc.C700095200","article-title":"Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells","volume":"282","author":"McNutt","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2016.02.026_bib58","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.02.026_bib59","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1161\/ATVBAHA.112.250571","article-title":"Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis","volume":"32","author":"Zhang","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kint.2016.02.026_bib60","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/ndt\/gft439","article-title":"Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome","volume":"29","author":"Liu","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2016.02.026_bib61","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1053\/j.ajkd.2013.10.042","article-title":"Hypercholesterolemia in nephrotic and peritoneal dialysis patients is associated with elevated plasma PCSK9 level","volume":"63","author":"Jin","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2016.02.026_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.272re3","article-title":"CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior","volume":"2","author":"Silverstein","year":"2009","journal-title":"Sci Signal"},{"key":"10.1016\/j.kint.2016.02.026_bib63","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","article-title":"PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver","volume":"35","author":"Demers","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kint.2016.02.026_bib64","doi-asserted-by":"crossref","first-page":"19055","DOI":"10.1074\/jbc.274.27.19055","article-title":"A\u00a0null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism","volume":"274","author":"Febbraio","year":"1999","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2016.02.026_bib65","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/bcp.12738","article-title":"Antisense-mediated reduction of proprotein convertase subtilisin\/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial","volume":"80","author":"van Poelgeest","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.kint.2016.02.026_bib66","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.kint.2016.02.026_bib67","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1172\/JCI80025","article-title":"Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects","volume":"125","author":"Millar","year":"2015","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2016.02.026_bib68","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/01.ATV.10.2.240","article-title":"Lipoprotein(a), fibrin binding, and plasminogen activation","volume":"10","author":"Loscalzo","year":"1990","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.kint.2016.02.026_bib69","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.02.026_bib70","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1161\/01.CIR.96.8.2514","article-title":"Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells","volume":"96","author":"Poon","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2016.02.026_bib71","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1523-1755.2004.00737.x","article-title":"Lipoprotein(a) and low-density lipoprotein-derived cholesterol in nephrotic syndrome: impact on lipid-lowering therapy?","volume":"66","author":"Kronenberg","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.02.026_bib72","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-119-4-199308150-00002","article-title":"Elevated plasma lipoprotein(a) in\u00a0patients with the nephrotic syndrome","volume":"119","author":"Wanner","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2016.02.026_bib73","first-page":"195","article-title":"Dyslipidemia and nephrotic syndrome: recent advances","volume":"15","author":"Kronenberg","year":"2005","journal-title":"J\u00a0Ren Nutr"},{"key":"10.1016\/j.kint.2016.02.026_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(96)90026-8","article-title":"Lipoprotein(a) in renal disease","volume":"27","author":"Kronenberg","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2016.02.026_bib75","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.2337\/db09-0538","article-title":"HDL as a biomarker, potential therapeutic target, and therapy","volume":"58","author":"Navab","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2016.02.026_bib76","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3389\/fphar.2015.00182","article-title":"The role of the lymphatic system in cholesterol transport","volume":"6","author":"Huang","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.kint.2016.02.026_bib77","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1161\/CIRCULATIONAHA.109.897330","article-title":"Adipocyte modulation of high-density lipoprotein cholesterol","volume":"121","author":"Zhang","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2016.02.026_bib78","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1172\/JCI30163","article-title":"Molecular regulation of HDL metabolism and function: implications for novel therapies","volume":"116","author":"Rader","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2016.02.026_bib79","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1161\/ATVBAHA.106.136325","article-title":"High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans","volume":"27","author":"Birjmohun","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kint.2016.02.026_bib80","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1681\/ASN.2011070668","article-title":"Serum amyloid A in uremic HDL promotes inflammation","volume":"23","author":"Weichhart","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2016.02.026_bib81","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1161\/01.ATV.15.11.1987","article-title":"High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules","volume":"15","author":"Cockerill","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kint.2016.02.026_bib82","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.atherosclerosis.2010.05.035","article-title":"Anti-inflammatory effects of apolipoprotein A-I in the rabbit","volume":"212","author":"Patel","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.kint.2016.02.026_bib83","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/ATVBAHA.108.168690","article-title":"High-density lipoprotein reduces the human monocyte inflammatory response","volume":"28","author":"Murphy","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kint.2016.02.026_bib84","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1440-1681.2010.05377.x","article-title":"High-density lipoproteins, platelets and\u00a0the pathogenesis of atherosclerosis","volume":"37","author":"Nofer","year":"2010","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.kint.2016.02.026_bib85","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1161\/01.RES.0000225982.01988.93","article-title":"Endothelial and antithrombotic actions of HDL","volume":"98","author":"Mineo","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2016.02.026_bib86","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1161\/01.ATV.15.8.1131","article-title":"Mildly oxidized LDL induces platelet aggregation through activation of phospholipase A2","volume":"15","author":"Weidtmann","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kint.2016.02.026_bib87","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1161\/01.ATV.17.10.2158","article-title":"HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL","volume":"17","author":"Suc","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kint.2016.02.026_bib88","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1161\/01.RES.74.6.1149","article-title":"High-density lipoprotein stimulates endothelial cell movement by a mechanism distinct from basic fibroblast growth factor","volume":"74","author":"Murugesan","year":"1994","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2016.02.026_bib89","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0021-9150(95)05774-9","article-title":"Effects of high-density lipoproteins on intracellular pH and proliferation of human vascular endothelial cells","volume":"123","author":"Tamagaki","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.kint.2016.02.026_bib90","first-page":"519","article-title":"High density lipoproteins and the growth of vascular endothelial cells in serum-free medium","volume":"17","author":"Tauber","year":"1981","journal-title":"In\u00a0Vitro"},{"key":"10.1016\/j.kint.2016.02.026_bib91","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2362.1977.tb01652.x","article-title":"Relationship among the concentrations of serum lipoproteins and changes in their chemical composition in patients with untreated nephrotic syndrome","volume":"7","author":"Gherardi","year":"1977","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.kint.2016.02.026_bib92","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0021-9150(85)90181-9","article-title":"Lipoprotein distribution and composition in the human nephrotic syndrome","volume":"54","author":"Muls","year":"1985","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.kint.2016.02.026_bib93","doi-asserted-by":"crossref","first-page":"F823","DOI":"10.1152\/ajprenal.2001.280.5.F823","article-title":"Acquired lecithin-cholesterol acyltransferase deficiency in nephrotic syndrome","volume":"280","author":"Vaziri","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2016.02.026_bib94","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1021\/bi952242v","article-title":"Serum albumin is a significant intermediate in cholesterol transfer between cells and lipoproteins","volume":"35","author":"Zhao","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.kint.2016.02.026_bib95","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0022-2275(20)41339-2","article-title":"Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome: role in dyslipidemia","volume":"33","author":"Moulin","year":"1992","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.kint.2016.02.026_bib96","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/01.ATV.17.11.2559","article-title":"Role of lipoprotein-bound NEFAs in enhancing the specific activity of plasma CETP in the nephrotic syndrome","volume":"17","author":"Braschi","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.kint.2016.02.026_bib97","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.clinbiochem.2007.04.016","article-title":"Effect of hypoalbuminemia on the increased serum cholesteryl ester transfer protein concentration in children with idiopathic nephrotic syndrome","volume":"40","author":"Zhang","year":"2007","journal-title":"Clin Biochem"},{"key":"10.1016\/j.kint.2016.02.026_bib98","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1126\/science.271.5248.518","article-title":"Identification of scavenger receptor SR-BI as a high density lipoprotein receptor","volume":"271","author":"Acton","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.kint.2016.02.026_bib99","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1046\/j.1523-1755.1999.00585.x","article-title":"Downregulation of hepatic high-density lipoprotein receptor, SR-B1 in nephrotic syndrome","volume":"56","author":"Liang","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.02.026_bib100","doi-asserted-by":"crossref","first-page":"6538","DOI":"10.1073\/pnas.100114397","article-title":"Identification of a PDZ-domain-containing protein that interacts with the scavenger receptor class B type I","volume":"97","author":"Ikemoto","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2016.02.026_bib101","first-page":"524","article-title":"Upregulation of hepatic HDL endocytic receptor and PDZK-1 dependent downregulation of HDL docking receptor in nephrotic syndrome","volume":"103","author":"Vaziri","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2016.02.026_bib102","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1161\/CIRCRESAHA.107.159079","article-title":"The scavenger receptor class B type I adaptor protein PDZK1 maintains endothelial monolayer integrity","volume":"102","author":"Zhu","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.kint.2016.02.026_bib103","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nature01250","article-title":"Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis","volume":"421","author":"Martinez","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.kint.2016.02.026_bib104","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10157-013-0847-z","article-title":"Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease","volume":"18","author":"Vaziri","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kint.2016.02.026_bib105","first-page":"S35","article-title":"Lipotoxicity and impaired HDL-mediated reverse cholesterol\/lipid transport in chronic kidney disease","volume":"20","author":"Vaziri","year":"2010","journal-title":"J\u00a0Ren Nutr"},{"key":"10.1016\/j.kint.2016.02.026_bib106","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(82)91513-6","article-title":"Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease","volume":"2","author":"Moorhead","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2016.02.026_bib107","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000170244","article-title":"Do glomerular atherosclerosis and lipid-mediated tubulo-interstitial disease cause progressive renal failure in man?","volume":"14","author":"Moorhead","year":"1996","journal-title":"Blood Purif"},{"key":"10.1016\/j.kint.2016.02.026_bib108","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrneph.2012.33","article-title":"Statins in the management of dyslipidemia associated with chronic kidney disease","volume":"8","author":"Epstein","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2016.02.026_bib109","unstructured":"Vaziri ND, Anzalone DA, Catini J. Statins in chronic kidney disease: when and when not to use them. J Fam Pract, in press."},{"key":"10.1016\/j.kint.2016.02.026_bib110","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","article-title":"Efficacy and\u00a0safety of longer-term administration of evolocumab (AMG 145) in\u00a0patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial","volume":"129","author":"Koren","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2016.02.026_bib111","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2016.02.026_bib112","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1161\/01.CIR.0000147777.12010.EF","article-title":"Effects of the acyl coenzyme A: cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions","volume":"110","author":"Tardif","year":"2004","journal-title":"Circulation"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253816300047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253816300047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T23:58:36Z","timestamp":1656633516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253816300047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0085253816300047"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2016.02.026","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2016.02.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016, International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}